ArticleMedical science monitor : international medical journal of experimental and clinical research2015
Down-Regulation of MiR-193a-3p Dictates Deterioration of HCC: A Clinical Real-Time qRT-PCR Study.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Utility of miR‑133a‑3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta‑analysis and bioinformatics.Molecular medicine reports · 2018Pooled it
- Downregulation of miR‑136‑5p in hepatocellular carcinoma and its clinicopathological significance.Molecular medicine reports · 2017Pooled it
- Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology.Oncotarget · 2021Article
- Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer.Molecular medicine reports · 2020Article
- Tumor Suppressor Role of hsa-miR-193a-3p and -5p in Cutaneous Melanoma.International journal of molecular sciences · 2020Article
- Article
- Research Progress on Long Non-Coding RNA and Radiotherapy.Medical science monitor : international medical journal of experimental and clinical research · 2019Review
- MiR-139-5p, miR-940 and miR-193a-5p inhibit the growth of hepatocellular carcinoma by targeting SPOCK1.Journal of cellular and molecular medicine · 2019Article
- Oncogenic value of microRNA-15b-5p in hepatocellular carcinoma and a bioinformatics investigation.Oncology letters · 2019Article
- Potential ceRNA networks involved in autophagy suppression of pancreatic cancer caused by chloroquine diphosphate: A study based on differentially‑expressed circRNAs, lncRNAs, miRNAs and mRNAs.International journal of oncology · 2019Article
- MiR-193a-3p inhibits pancreatic ductal adenocarcinoma cell proliferation by targeting CCND1.Cancer management and research · 2019Article
- The clinicopathological significance of decreased miR-125b-5p in hepatocellular carcinoma: evidence based on RT-qPCR, microRNA-microarray, and microRNA-sequencing.International journal of clinical and experimental pathology · 2019Article
- Knockdown long noncoding RNA nuclear paraspeckle assembly transcript 1 suppresses colorectal cancer through modulating miR-193a-3p/KRAS.Cancer medicine · 2019Article
- MicroRNA-124-3p expression and its prospective functional pathways in hepatocellular carcinoma: A quantitative polymerase chain reaction, gene expression omnibus and bioinformatics study.Oncology letters · 2018Article
- Potential targets and clinical value of miR-490-5p in hepatocellular carcinoma: a study based on TCGA, qRT-PCR and bioinformatics analyses.International journal of clinical and experimental pathology · 2018Article
- The clinical value of miR-193a-3p in non-small cell lung cancer and its potential molecular mechanism exploredFEBS open bio · 2018Article
- Article
- Role of the long non-coding RNA HOTAIR in hepatocellular carcinoma.Oncology letters · 2017Article
- Clinical and biological significance of miR-23b and miR-193a in human hepatocellular carcinoma.Oncotarget · 2017Article
- A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma.OncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough some recent reports have shown that the expression level of miR-193a varied in different cancers, its role in hepatocellular carcinoma (HCC) remains unidentified. The aim of the current study was to validate the relationship between miR-193a-3p and clinicopathological characteristics in HCC patients. MATERIAL AND
methodsExpression of miR-193a-3p in 95 HCC cases and their corresponding peritumoral tissues (PT) was examined by using quantitative reverse transcription polymerase chain reaction (qRT-PCR). miR-193a-3p expression and its correlation with a variety of clinicopathological features and patient recurrence were analyzed.
resultsThe relative level of miR-193a-3p was 3.2028±1.1951 in PT, significantly higher than its expression in HCC tissues (1.5941±0.7079, P<0.001). The area under the curve of underexpression of miR-193a-3p was 0.906 to distinguish HCC from normal liver (95% CI: 0.864-0.948, P<0.001). Expression of miR-193a-3p was negatively correlated to metastasis (r=-0.371, P=0.000), TNM (r=-0.321, P=0.002), respectively. Additionally, the recurrence time was 50.271±2.631 months for the low miR-193a-3p level group and 60.132±3.626 months for the high miR-193a-3p level group. However, no significant difference between them was found (chi-square=0.354, P=0.552).
conclusionsMiR-193a-3p may be a tumor-suppressive miRNA which is down-regulated in HCC tissues. It could be regarded as a predictor for the deterioration of HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.